Yttrium-90 resin microspheres as an adjunct to sorafenib in patients with unresectable hepatocellular carcinoma

por Mahvash, Armeen, Murthy, Ravi, Odisio, Bruno C, Raghav, Kanwal Pratap, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Ensor, Joe, Gadani, Sameer, Elsayes, Khaled M, Abdel-Wahab, Reham, Hassan, Manal, Shalaby, Ahmed S, Yao, James C, Wallace, Michael J, Kaseb, Ahmed O
Publicado 2016

Phase II trial of bevacizumab and erlotinib as a second-line therapy for advanced hepatocellular carcinoma

por Kaseb, Ahmed O, Morris, Jeffrey S, Iwasaki, Michiko, Al-Shamsi, Humaid O, Raghav, Kanwal Pratap Singh, Girard, Lauren, Cheung, Sheree, Nguyen, Van, Elsayes, Khaled M, Xiao, Lianchun, Abdel-Wahab, Reham, Shalaby, Ahmed S, Hassan, Manal, Hassabo, Hesham M, Wolff, Robert A, Yao, James C
Publicado 2016

A Prospective Phase II Study of Safety and Efficacy of Sorafenib Followed by (90)Y Glass Microspheres for Patients with Advanced or Metastatic Hepatocellular Carcinoma

por Kaseb, Ahmed Omar, Kappadath, S Cheenu, Lee, Sunyoung S, Raghav, Kanwal Pratap, Mohamed, Yehia I, Xiao, Lianchun, Morris, Jeffrey S, Ohaji, Chimela, Avritscher, Rony, Odisio, Bruno C, Kuban, Joshua, Abdelsalam, Mohamed E, Chasen, Beth, Elsayes, Khaled M, Elbanan, Mohamed, Wolff, Robert A, Yao, James C, Mahvash, Armeen
Publicado 2021